Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in MSS
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Balimek
Treatment of unresectable or metastatic melanoma. Treatment of unresectable melanoma, with NRA Q61 mutation.
View on EMAMektovi
MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
View on EMAVaccines, Pneumococcal
Renal Transplantation
Diabetes Mellitus
Major Depressive Disorder
Complicated Intra-abdominal Infections